These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 14630791

  • 1. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.
    Blood; 2004 Mar 15; 103(6):2039-45. PubMed ID: 14630791
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.
    Blood; 1999 Sep 01; 94(5):1550-4. PubMed ID: 10477679
    [Abstract] [Full Text] [Related]

  • 4. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE.
    Am J Hematol; 2016 Feb 01; 91(2):238-42. PubMed ID: 26615793
    [Abstract] [Full Text] [Related]

  • 5. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 01; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R, Hsieh MM, Zhao X, Calvaruso G, Rigano P, Renda D, Tisdale JF, Maggio A.
    Int J Mol Sci; 2018 Feb 28; 19(3):. PubMed ID: 29495591
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE.
    N Engl J Med; 2020 Jun 25; 382(26):2524-2533. PubMed ID: 32579813
    [Abstract] [Full Text] [Related]

  • 11. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN, Olupot-Olupot P, Stuber SE, Tomlinson G, Latham T, Ware RE, REACH Investigators.
    Lancet Haematol; 2024 Jun 25; 11(6):e425-e435. PubMed ID: 38701812
    [Abstract] [Full Text] [Related]

  • 12. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
    Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP, Girot R, Elion J.
    Blood; 1998 Jun 15; 91(12):4472-9. PubMed ID: 9616141
    [Abstract] [Full Text] [Related]

  • 13. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P, De Franceschi L, Sainati L, Piga A, Piel FB, Cappellini MD, Fidone C, Masera N, Palazzi G, Gianesin B, Forni GL, Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators.
    Blood Cells Mol Dis; 2018 Mar 15; 69():82-89. PubMed ID: 29107441
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.
    Pediatrics; 2008 Dec 15; 122(6):1332-42. PubMed ID: 19047254
    [Abstract] [Full Text] [Related]

  • 16. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
    Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C, Aygun B, Ware RE, Nottage K, Hankins JS.
    Am J Hematol; 2017 Dec 15; 92(12):1333-1339. PubMed ID: 28913922
    [Abstract] [Full Text] [Related]

  • 17. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
    Quinn CT, Niss O, Dong M, Pfeiffer A, Korpik J, Reynaud M, Bonar H, Kalfa TA, Smart LR, Malik P, Ware RE, Vinks AA, McGann PT.
    Br J Haematol; 2021 Aug 15; 194(3):617-625. PubMed ID: 34227124
    [Abstract] [Full Text] [Related]

  • 18. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW, Al-Hajri M, Beshlawi I, Al-Shahrabally A, Elshinawy M, Zachariah M, Mevada ST, Bashir W, Rawas A, Taqi A, Al-Lamki Z, Wali Y.
    Eur J Haematol; 2013 Jun 15; 90(6):519-24. PubMed ID: 23489171
    [Abstract] [Full Text] [Related]

  • 19. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
    Ware RE, Zimmerman SA, Schultz WH.
    Blood; 1999 Nov 01; 94(9):3022-6. PubMed ID: 10556185
    [Abstract] [Full Text] [Related]

  • 20. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
    Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE.
    Am J Hematol; 2013 Feb 01; 88(2):116-9. PubMed ID: 23255310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.